Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 331

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.

Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)

Open access
Cordonnier, Catherine, Einarsdottir, Sigrun, Cesaro, Simone, Di Blasi, Roberta, Mikulska, Malgorzata, Rieger, Christina, de Lavallade, Hugues, Gallo, Giuseppe, Lehrnbecher, Thomas, Engelhard, Dan, Ljungman, Per·2019·The Lancet Infectious Diseases
DOI 10.1016/s1473-3099(18)30600-5
Open this paper in CoChat — free account

Abstract

Infection is a main concern after haemopoietic stem cell transplantation (HSCT) and a major cause of transplant-related mortality. Some of these infections are preventable by vaccination. Most HSCT recipients lose their immunity to various pathogens as soon as the first months after transplant, irrespective of the pre-transplant donor or recipient vaccinations. Vaccination with inactivated vaccines is safe after transplantation and is an effective way to reinstate protection from various pathogens (eg, influenza virus and Streptococcus pneumoniae), especially for pathogens whose risk of infection is increased by the transplant procedure. The response to vaccines in patients with transplants is usually lower than that in healthy individuals of the same age during the first months or years after transplant, but it improves over time to become close to normal 2-3 years after the procedure. However, because immunogenic vaccines have been found to induce a response in a substantial proportion of the patients as early as 3 months after transplant, we recommend to start crucial vaccinations with inactivated vaccines from 3 months after transplant, irrespectively of whether the patient has or has not developed graft-versus-host disease (GvHD) or received immunosuppressants. Patients with GvHD have higher risk of infection and are likely to benefit from vaccination. Another challenge is to provide HSCT recipients the same level of vaccine protection as healthy individuals of the same age in a given country. The use of live attenuated vaccines should be limited to specific situations because of the risk of vaccine-induced disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(18)30600-5

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 101 references

Research works printed but not linked: 41

  1. Sheridan, 1990, Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation, Blood, 75, 1583, 10.1182/blood.V75.7.1583.1583 · doi:10.1182/blood.v75.7.1583.1583
  2. Meerveld-Eggink, 2009, Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 15, 1523, 10.1016/j.bbmt.2009.07.020 · doi:10.1016/j.bbmt.2009.07.020
  3. Pauksen, 1992, Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation, Bone Marrow Transplant, 9, 427
  4. Ljungman, 2005, Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT, Bone Marrow Transplant, 35, 737, 10.1038/sj.bmt.1704870 · doi:10.1038/sj.bmt.1704870
  5. Debbache, 2009, The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines?, Clin Microbiol Infect, 15, 865, 10.1111/j.1469-0691.2009.02810.x · doi:10.1111/j.1469-0691.2009.02810.x
  6. Cordonnier, 2010, Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant, Bone Marrow Transplant, 45, 1423, 10.1038/bmt.2009.364 · doi:10.1038/bmt.2009.364
  7. Cordonnier, 2015, Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial, Bone Marrow Transplant, 50, 1, 10.1038/bmt.2015.42 · doi:10.1038/bmt.2015.42
  8. Olkinuora, 2012, Immunity after (re)vaccination of paediatric patients following haematopoietic stem cell transplantation, Acta Paediatr, 101, e373, 10.1111/j.1651-2227.2012.02710.x · doi:10.1111/j.1651-2227.2012.02710.x
  9. Antin, 2005, Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 11, 213, 10.1016/j.bbmt.2004.12.330 · doi:10.1016/j.bbmt.2004.12.330
  10. Cordonnier, 1986, Pulmonary complications occurring after allogeneic bone marrow transplantation. A study of 130 consecutive transplanted patients, Cancer, 58, 1047, 10.1002/1097-0142(19860901)58:5<1047::AID-CNCR2820580512>3.0.CO;2-Y · doi:10.1002/1097-0142(19860901)58:5<1047::aid-cncr2820580512>3.0.co;2-y
  11. Aucouturier, 1987, Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation, Blood, 70, 779, 10.1182/blood.V70.3.779.779 · doi:10.1182/blood.v70.3.779.779
  12. Molrine, 1996, Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation, Bone Marrow Transplant, 17, 1149
  13. Parkkali, 1999, IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines, Bone Marrow Transplant, 24, 671, 10.1038/sj.bmt.1701967 · doi:10.1038/sj.bmt.1701967
  14. Chan, 1997, Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT), Bone Marrow Transplant, 20, 33, 10.1038/sj.bmt.1700843 · doi:10.1038/sj.bmt.1700843
  15. Whittaker, 2017, Epidemiology of invasive Haemophilus influenzae disease, Europe, 2007–2014, Emerg Infect Dis, 23, 396, 10.3201/eid2303.161552 · doi:10.3201/eid2303.161552
  16. Parkkali, 2001, Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients, Bone Marrow Transplant, 27, 79, 10.1038/sj.bmt.1702742 · doi:10.1038/sj.bmt.1702742
  17. Heininger, 2016, Comparative epidemiologic characteristics of pertussis in 10 central and eastern European countries, 2000–2013, PLoS One, 11, e0155949, 10.1371/journal.pone.0155949 · DOI
  18. Suzuki, 2003, Pertussis in adolescence after unrelated cord blood transplantation, Bone Marrow Transplant, 32, 967, 10.1038/sj.bmt.1704250 · doi:10.1038/sj.bmt.1704250
  19. Yacoub, 2016, Infectious disease report: Bordetella pertussis infection in patients with cancer, Cancer Control, 23, 163, 10.1177/107327481602300211 · doi:10.1177/107327481602300211
  20. Machado, 2005, The benefit of influenza vaccination after bone marrow transplantation, Bone Marrow Transplant, 36, 897, 10.1038/sj.bmt.1705159 · doi:10.1038/sj.bmt.1705159
  21. Engelhard, 1993, Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients, Bone Marrow Transplant, 11, 1
  22. Natori, 2017, A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients, Bone Marrow Transplant, 52, 1016, 10.1038/bmt.2017.24 · doi:10.1038/bmt.2017.24
  23. Ambati, 2015, Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study, Bone Marrow Transplant, 50, 858, 10.1038/bmt.2015.47 · doi:10.1038/bmt.2015.47
  24. Karras, 2013, A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation, Biol Blood Marrow Transplant, 19, 109, 10.1016/j.bbmt.2012.08.015 · doi:10.1016/j.bbmt.2012.08.015
  25. Dhédin, 2014, Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients, Vaccine, 32, 585, 10.1016/j.vaccine.2013.11.073 · doi:10.1016/j.vaccine.2013.11.073
  26. Issa, 2011, Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients, Biol Blood Marrow Transplant, 17, 434, 10.1016/j.bbmt.2010.10.002 · doi:10.1016/j.bbmt.2010.10.002
  27. Fukatsu, 2017, Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at >1 year after undergoing allogeneic hematopoietic stem cell transplantation, Int J Hematol, 105, 638, 10.1007/s12185-016-2163-3 · doi:10.1007/s12185-016-2163-3
  28. Parkkali, 1996, Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation, Apmis, 104, 383, 10.1111/j.1699-0463.1996.tb00731.x · doi:10.1111/j.1699-0463.1996.tb00731.x
  29. Ljungman, 2004, Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients, Bone Marrow Transplant, 34, 1067, 10.1038/sj.bmt.1704678 · doi:10.1038/sj.bmt.1704678
  30. Ilan, 1993, Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation, Hepatology, 18, 246, 10.1002/hep.1840180204 · doi:10.1002/hep.1840180204
  31. Kaloyannidis, 2007, Allografted recipients immunized against hepatitis B virus are at high risk of gradual surface antibody (HbsAb) disappearance post transplant, regardless of adoptive immunity transfer, Biol Blood Marrow Transplant, 13, 1049, 10.1016/j.bbmt.2007.05.009 · doi:10.1016/j.bbmt.2007.05.009
  32. Hui, 2005, Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area, J Hepatol, 42, 813, 10.1016/j.jhep.2005.01.018 · doi:10.1016/j.jhep.2005.01.018
  33. Le, 2009, Lamivudine prophylaxis and hepatitis B vaccination for prevention of hepatitis B virus reverse seroconversion in long-term survivors after allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 15, 886, 10.1016/j.bbmt.2009.03.024 · doi:10.1016/j.bbmt.2009.03.024
  34. MacIntyre, 2016, Immunogenicity and persistence of immunity of a quadrivalent human papillomavirus (HPV) vaccine in immunocompromised children, Vaccine, 34, 4343, 10.1016/j.vaccine.2016.06.049 · doi:10.1016/j.vaccine.2016.06.049
  35. Costa, 2016, Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient, BMJ Case Rep, 2016, 10.1136/bcr-2015-212688 · doi:10.1136/bcr-2015-212688
  36. Ljungman, 2003, Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study, Support Care Cancer, 11, 739
  37. Sasadeusz, 2014, Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation, Transpl Infect Dis, 16, 1024, 10.1111/tid.12295 · doi:10.1111/tid.12295
  38. Aoki, 2016, Safety of live attenuated high-titer varicella-zoster virus vaccine in pediatric allogeneic hematopoietic stem cell transplantation recipients, Biol Blood Marrow Transplant, 22, 771, 10.1016/j.bbmt.2015.12.025 · doi:10.1016/j.bbmt.2015.12.025
  39. Machado, 2002, Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil, Blood, 99, 83, 10.1182/blood.V99.1.83 · DOI
  40. Wimperis, 1990, Requirements for the adoptive transfer of antibody responses to a priming antigen in man, J Immunol, 144, 541, 10.4049/jimmunol.144.2.541 · doi:10.4049/jimmunol.144.2.541
  41. Harris, 2015, Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection?, Bone Marrow Transplant, 50, 899, 10.1038/bmt.2015.49 · doi:10.1038/bmt.2015.49

Cited by

See all 331

Metadata

Authors
Cordonnier, C., Einarsdottir, S., Cesaro, S., Di Blasi, R., Mikulska, M., Rieger, C., de Lavallade, H., Gallo, G., Lehrnbecher, T., Engelhard, D., & Ljungman, P.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2019-06
Volume
19
Issue
6
Pages
e200-e212
ISSN
1473-3099 (ISSN-L)
DOI
10.1016/s1473-3099(18)30600-5
OpenAlex
W2914146049
Cited by
331
References
101
FWCI
25.23
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Basilea Pharmaceutica
  • Gilead Sciences
  • Astellas Pharma
  • Meso Scale Diagnostics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). https://app.cochat.ai/papers/10.1016/s1473-3099(18)30600-5
The paper
Cordonnier, C., Einarsdottir, S., Cesaro, S., Di Blasi, R., Mikulska, M., Rieger, C., de Lavallade, H., Gallo, G., Lehrnbecher, T., Engelhard, D., & Ljungman, P. (2019). Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(18)30600-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.